Changes

__TOC__

__TOC__

==Cancer Category/Type==

==Cancer Category/Type==

{| class="wikitable sortable"

{| class="wikitable sortable"

|-

|-

! Finding   !! Marker

!Finding!!Marker

|-

|-

|Positive (universal) || EXAMPLE CD1

|Positive (universal)||EXAMPLE CD1

|-

|-

|Positive (subset) || EXAMPLE CD2

|Positive (subset)||EXAMPLE CD2

|-

|-

|Negative (universal) || EXAMPLE CD3

|Negative (universal)||EXAMPLE CD3

|-

|-

|Negative (subset) || EXAMPLE CD4

|Negative (subset)||EXAMPLE CD4

|}

|}

{| class="wikitable sortable"

{| class="wikitable sortable"

|-

|-

! Chromosomal Rearrangement !! Genes in Fusion (5’ or 3’ Segments) !! Pathogenic Derivative !! Prevalence

!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence

|-

|-

|EXAMPLE t(9;22)(q34;q11.2) || EXAMPLE 3'ABL1 / 5'BCR || EXAMPLE der(22) || EXAMPLE 5%

|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 5%

|-

|-

|EXAMPLE t(8;21)(q22;q22) || EXAMPLE 5'RUNX1 / 3'RUNXT1 || EXAMPLE der(8) || EXAMPLE 5%

|EXAMPLE t(8;21)(q22;q22)||EXAMPLE 5'RUNX1 / 3'RUNXT1||EXAMPLE der(8)||EXAMPLE 5%

|}

|}

{| class="wikitable sortable"

{| class="wikitable sortable"

|-

|-

! Chromosome Number !! Gain/Loss/Amp/LOH !! Region

!Chromosome Number!!Gain/Loss/Amp/LOH!!Region

|-

|-

|EXAMPLE 8 || EXAMPLE Gain || EXAMPLE chr8:0-1000000

|EXAMPLE 8||EXAMPLE Gain||EXAMPLE chr8:0-1000000

|-

|-

|EXAMPLE 7 || EXAMPLE Loss || EXAMPLE chr7:0-1000000

|EXAMPLE 7||EXAMPLE Loss||EXAMPLE chr7:0-1000000

|}

|}

{| class="wikitable sortable"

{| class="wikitable sortable"

|-

|-

! Gene !! Mutation !! Oncogene/Tumor Suppressor/Other !! Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) !! Prevalence (COSMIC/TCGA/Other)

!Gene!!Mutation!!Oncogene/Tumor Suppressor/Other!!Presumed Mechanism (LOF/GOF/Other; Driver/Passenger)!!Prevalence (COSMIC/TCGA/Other)

|-

|-

| EXAMPLE TP53 || EXAMPLE R273H || EXAMPLE Tumor Suppressor || EXAMPLE LOF || EXAMPLE 20%

|EXAMPLE TP53||EXAMPLE R273H||EXAMPLE Tumor Suppressor||EXAMPLE LOF||EXAMPLE 20%

|}

|}

{| class="wikitable sortable"

{| class="wikitable sortable"

|-

|-

! Type !! Gene/Region/Other

!Type!!Gene/Region/Other

|-

|-

| Concomitant Mutations || EXAMPLE IDH1 R123H

|Concomitant Mutations||EXAMPLE IDH1 R123H

|-

|-

| Secondary Mutations || EXAMPLE Trisomy 7

|Secondary Mutations||EXAMPLE Trisomy 7

|-

|-

|Mutually Exclusive || EXAMPLE EGFR Amplification

|Mutually Exclusive||EXAMPLE EGFR Amplification

|}

|}

==References==

==References==

=== EXAMPLE Book ===

===EXAMPLE Book===

 

#Arber DA, et al., (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4thedition.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118.

#Arber DA, et al., (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4thedition.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118.

=== EXAMPLE Journal Article ===

===EXAMPLE Journal Article===

 

#Li Y, et al., (2001). Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 28:220-221, PMID 11431691.

#Li Y, et al., (2001). Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 28:220-221, PMID 11431691.

== Notes ==

==Notes==

<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.

<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.